Smith & Nephew Chief Executive Officer: "No fundamental slowdown in orthopaedics market"
This article was originally published in Clinica
While analysts and the media have jumped to conclusions about slowing growth in the orthopaedics industry, Smith & Nephew's unflappable chief executive Sir Christopher O'Donnell takes a more measured approach. He talks to Clinica's Eleanor Malone about the UK firm's position in the light of strong third-quarter results.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.